Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

(2011) E. P. Hui et al.   ANNALS OF ONCOLOGY

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

(2010) S. Antoun et al.   ANNALS OF ONCOLOGY

Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420

(2010) Stephen K. Williamson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

(2009) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

(2009) Jean-Pascal H. Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

(2009) Youjin Je et al.   LANCET ONCOLOGY

Transarterial Embolization for Control of Bleeding in Patients with Head and Neck Cancer

(2009) Yung-Fang Chen et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Chemotherapy-Induced Recall of Cetuximab and Radiation Skin Reaction

(2008) A.B. Law et al.   CLINICAL ONCOLOGY